Athanor Capital’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Athanor Capital’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-24,398	Closed	-$624K	–	979
2021 Q1	$624K	Sell	24,398 -17,799	-42%	-$455K	0.01%	429
2020 Q4	$930K	Sell	42,197 -3,304	-7%	-$72.8K	0.02%	339
2020 Q3	$819K	Buy	45,501 +37,619	+477%	+$779K	0.03%	269
2020 Q2	$200K	Buy	+7,882	New	+$170K	0.01%	501
2020 Q1	–	Sell	-24,350	Closed	-$536K	–	406
2019 Q4	$536K	Buy	+24,350	New	+$490K	0.02%	237
2019 Q3	–	Sell	-14,800	Closed	-$233K	–	243
2019 Q2	$233K	Buy	+14,800	New	+$201K	0.03%	123

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Athanor Capital's DRNA Position: Q2 2021 in Review

Athanor Capital sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q2 2021, closing a stake of 24,398 shares — an estimated $624K sold.

Athanor Capital first reported a position in DRNA in Q2 2019 and held it in 6 quarters. The position peaked at $930K in Q4 2020. 203 funds tracked by Wall St. Rank hold DRNA as of Q2 2021.

Athanor Capital reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
Athanor Capital sold 24,398 Dicerna Pharmaceuticals, Inc. shares in Q2 2021, an estimated $624K.
Athanor Capital first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2019 and held it in 6 quarters.
Athanor Capital's Dicerna Pharmaceuticals, Inc. position peaked at $930K in Q4 2020.
203 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q2 2021.

Based on Athanor Capital's 13F filing for Q2 2021, filed 16 Aug 2021.